Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

Joshua K. Wong; Helen S. Mayberg; Doris D. Wang; R. Mark Richardson; Casey H. Halpern; Lothar Krinke; Mattia Arlotti; Lorenzo Rossi; Alberto Priori; Sara Marceglia; Ro’ee Gilron; James F. Cavanagh; Jack W. Judy; Svjetlana Miocinovic; Annaelle D. Devergnas; Roy V. Sillitoe; Stephanie Cernera; Carina R. Oehrn; Aysegul Gunduz; Wayne K. Goodman; Erika A. Petersen; Helen Bronte-Stewart; Robert S. Raike; Mahsa Malekmohammadi; David Greene; Petra Heiden; Huiling Tan; Jens Volkmann; Valerie Voon; Luming Li; Pankaj Sah; Terry Coyne; Peter A. Silburn; Cynthia S. Kubu; Anna Wexler; Jennifer Chandler; Nicole R. Provenza; Sarah R. Heilbronner; Marta San Luciano; Christopher J. Rozell; Michael D. Fox; Coralie de Hemptinne; Jaimie M. Henderson; Sameer A. Sheth; Michael S. Okun

doi:10.3389/fnhum.2022.1084782

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

Joshua K. Wong, Helen S. Mayberg, Doris D. Wang, R. Mark Richardson, Casey H. Halpern, Lothar Krinke, Mattia Arlotti, Lorenzo Rossi, Alberto Priori, Sara Marceglia, Ro’ee Gilron, James F. Cavanagh, Jack W. Judy, Svjetlana Miocinovic, Annaelle D. Devergnas, Roy V. Sillitoe, Stephanie Cernera, Carina R. Oehrn, Aysegul Gunduz, Wayne K. GoodmanErika A. Petersen, Helen Bronte-Stewart, Robert S. Raike, Mahsa Malekmohammadi, David Greene, Petra Heiden, Huiling Tan, Jens Volkmann, Valerie Voon, Luming Li, Pankaj Sah, Terry Coyne, Peter A. Silburn, Cynthia S. Kubu, Anna Wexler, Jennifer Chandler, Nicole R. Provenza, Sarah R. Heilbronner, Marta San Luciano, Christopher J. Rozell, Michael D. Fox, Coralie de Hemptinne, Jaimie M. Henderson, Sameer A. Sheth, Michael S. Okun

Research output: Contribution to journal › Article › peer-review

Abstract

The deep brain stimulation (DBS) Think Tank X was held on August 17–19, 2022 in Orlando FL. The session organizers and moderators were all women with the theme women in neuromodulation. Dr. Helen Mayberg from Mt. Sinai, NY was the keynote speaker. She discussed milestones and her experiences in developing depression DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging DBS technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank X speakers was that DBS has continued to expand in scope however several indications have reached the “trough of disillusionment.” DBS for depression was considered as “re-emerging” and approaching a slope of enlightenment. DBS for depression will soon re-enter clinical trials. The group estimated that globally more than 244,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year’s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia, and Australia; cutting-edge technologies, closed loop DBS, DBS tele-health, neuroethics, lesion therapy, interventional psychiatry, and adaptive DBS.

Original language	English
Article number	1084782
Journal	Frontiers in Human Neuroscience
Volume	16
DOIs	https://doi.org/10.3389/fnhum.2022.1084782
State	Published - 27 Jan 2023

Keywords

Parkinson’s disease
adaptive DBS
artificial intelligence
deep brain stimulation (DBS)
dystonia
epilepsy
interventional psychiatry
neuroethics

Access to Document

10.3389/fnhum.2022.1084782

Fingerprint

Dive into the research topics of 'Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation'. Together they form a unique fingerprint.

Cite this

Wong, J. K., Mayberg, H. S., Wang, D. D., Richardson, R. M., Halpern, C. H., Krinke, L., Arlotti, M., Rossi, L., Priori, A., Marceglia, S., Gilron, R., Cavanagh, J. F., Judy, J. W., Miocinovic, S., Devergnas, A. D., Sillitoe, R. V., Cernera, S., Oehrn, C. R., Gunduz, A., ... Okun, M. S. (2023). Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation. Frontiers in Human Neuroscience, 16, [1084782]. https://doi.org/10.3389/fnhum.2022.1084782

@article{6e5984a822404e0f9482c886f8685f9e,

title = "Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation",

abstract = "The deep brain stimulation (DBS) Think Tank X was held on August 17–19, 2022 in Orlando FL. The session organizers and moderators were all women with the theme women in neuromodulation. Dr. Helen Mayberg from Mt. Sinai, NY was the keynote speaker. She discussed milestones and her experiences in developing depression DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging DBS technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank X speakers was that DBS has continued to expand in scope however several indications have reached the “trough of disillusionment.” DBS for depression was considered as “re-emerging” and approaching a slope of enlightenment. DBS for depression will soon re-enter clinical trials. The group estimated that globally more than 244,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year{\textquoteright}s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia, and Australia; cutting-edge technologies, closed loop DBS, DBS tele-health, neuroethics, lesion therapy, interventional psychiatry, and adaptive DBS.",

keywords = "Parkinson{\textquoteright}s disease, adaptive DBS, artificial intelligence, deep brain stimulation (DBS), dystonia, epilepsy, interventional psychiatry, neuroethics",

author = "Wong, {Joshua K.} and Mayberg, {Helen S.} and Wang, {Doris D.} and Richardson, {R. Mark} and Halpern, {Casey H.} and Lothar Krinke and Mattia Arlotti and Lorenzo Rossi and Alberto Priori and Sara Marceglia and Ro{\textquoteright}ee Gilron and Cavanagh, {James F.} and Judy, {Jack W.} and Svjetlana Miocinovic and Devergnas, {Annaelle D.} and Sillitoe, {Roy V.} and Stephanie Cernera and Oehrn, {Carina R.} and Aysegul Gunduz and Goodman, {Wayne K.} and Petersen, {Erika A.} and Helen Bronte-Stewart and Raike, {Robert S.} and Mahsa Malekmohammadi and David Greene and Petra Heiden and Huiling Tan and Jens Volkmann and Valerie Voon and Luming Li and Pankaj Sah and Terry Coyne and Silburn, {Peter A.} and Kubu, {Cynthia S.} and Anna Wexler and Jennifer Chandler and Provenza, {Nicole R.} and Heilbronner, {Sarah R.} and Luciano, {Marta San} and Rozell, {Christopher J.} and Fox, {Michael D.} and {de Hemptinne}, Coralie and Henderson, {Jaimie M.} and Sheth, {Sameer A.} and Okun, {Michael S.}",

note = "Funding Information: JW research was supported by NIH KL2TR001429. HM research was supported by NIH BRAIN UH3 NS103550 and Hope for Depression Research Foundation. DW research was supported by Michael J. Fox Foundation, Burroughs-Wellcome Career Award for Medical Scientists, and UCSF Weill Institute for Neurosciences. JaC research was funded by R01MH119382. SMi research was supported by NIH K23NS097576. RS research was funded by NIH R01NS100874, R01NS119301, R01NS127435, and P50HD103555. CO research was funded by the Thiemann Foundation and by NIH UH3NS100544. AG research was supported by NIH R01NS096008 and NSF Career Award 1553482. WG acknowledges grant funding from NIH UH3NS100549. HT research was supported by the Medical Research Council UK (MC_UU_00003/2, MR/V00655X/1, and MR/P012272/1), the NIHR, Oxford Biomedical Research Centre, and the Rosetrees Trust. JV gratefully acknowledges grant support by the Deutsche Forschungsgemeinschaft within the framework of CRC-TRR 295 (Retune). PaS, TC, and PeS research was funded by the University of Queensland through the Queensland Brain Institute in partnership with Medtronic. JeC work was supported by the Canadian Institutes of Health Research within the funding framework Network of European Funding for Neuroscience Research (NEURON) under the ERA-NET scheme of the European Commission. ML research was supported by NIH 5K23NS099441. CR research was supported by NIH UH3NS103550. JH research was supported by NIH R01DC014034, U01DC017844, UH2NS095548, and U01NS098968. MO served as a consultant for the Parkinson{\textquoteright}s Foundation and has received research grants from NIH, Parkinson{\textquoteright}s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation, DBS research was supported by: NIH R01 NR014852 and R01NS096008, and PI of the NIH R25NS108939 Training Grant. Publisher Copyright: Copyright {\textcopyright} 2023 Wong, Mayberg, Wang, Richardson, Halpern, Krinke, Arlotti, Rossi, Priori, Marceglia, Gilron, Cavanagh, Judy, Miocinovic, Devergnas, Sillitoe, Cernera, Oehrn, Gunduz, Goodman, Petersen, Bronte-Stewart, Raike, Malekmohammadi, Greene, Heiden, Tan, Volkmann, Voon, Li, Sah, Coyne, Silburn, Kubu, Wexler, Chandler, Provenza, Heilbronner, Luciano, Rozell, Fox, de Hemptinne, Henderson, Sheth and Okun.",

year = "2023",

month = jan,

day = "27",

doi = "10.3389/fnhum.2022.1084782",

language = "English",

volume = "16",

journal = "Frontiers in Human Neuroscience",

issn = "1662-5161",

publisher = "Frontiers Media S.A.",

}

Wong, JK, Mayberg, HS, Wang, DD, Richardson, RM, Halpern, CH, Krinke, L, Arlotti, M, Rossi, L, Priori, A, Marceglia, S, Gilron, R, Cavanagh, JF, Judy, JW, Miocinovic, S, Devergnas, AD, Sillitoe, RV, Cernera, S, Oehrn, CR, Gunduz, A, Goodman, WK, Petersen, EA, Bronte-Stewart, H, Raike, RS, Malekmohammadi, M, Greene, D, Heiden, P, Tan, H, Volkmann, J, Voon, V, Li, L, Sah, P, Coyne, T, Silburn, PA, Kubu, CS, Wexler, A, Chandler, J, Provenza, NR, Heilbronner, SR, Luciano, MS, Rozell, CJ, Fox, MD, de Hemptinne, C, Henderson, JM, Sheth, SA & Okun, MS 2023, 'Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation', Frontiers in Human Neuroscience, vol. 16, 1084782. https://doi.org/10.3389/fnhum.2022.1084782

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation. / Wong, Joshua K.; Mayberg, Helen S.; Wang, Doris D. et al.
In: Frontiers in Human Neuroscience, Vol. 16, 1084782, 27.01.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Proceedings of the 10th annual deep brain stimulation think tank

T2 - Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

AU - Wong, Joshua K.

AU - Mayberg, Helen S.

AU - Wang, Doris D.

AU - Richardson, R. Mark

AU - Halpern, Casey H.

AU - Krinke, Lothar

AU - Arlotti, Mattia

AU - Rossi, Lorenzo

AU - Priori, Alberto

AU - Marceglia, Sara

AU - Gilron, Ro’ee

AU - Cavanagh, James F.

AU - Judy, Jack W.

AU - Miocinovic, Svjetlana

AU - Devergnas, Annaelle D.

AU - Sillitoe, Roy V.

AU - Cernera, Stephanie

AU - Oehrn, Carina R.

AU - Gunduz, Aysegul

AU - Goodman, Wayne K.

AU - Petersen, Erika A.

AU - Bronte-Stewart, Helen

AU - Raike, Robert S.

AU - Malekmohammadi, Mahsa

AU - Greene, David

AU - Heiden, Petra

AU - Tan, Huiling

AU - Volkmann, Jens

AU - Voon, Valerie

AU - Li, Luming

AU - Sah, Pankaj

AU - Coyne, Terry

AU - Silburn, Peter A.

AU - Kubu, Cynthia S.

AU - Wexler, Anna

AU - Chandler, Jennifer

AU - Provenza, Nicole R.

AU - Heilbronner, Sarah R.

AU - Luciano, Marta San

AU - Rozell, Christopher J.

AU - Fox, Michael D.

AU - de Hemptinne, Coralie

AU - Henderson, Jaimie M.

AU - Sheth, Sameer A.

AU - Okun, Michael S.

N1 - Funding Information: JW research was supported by NIH KL2TR001429. HM research was supported by NIH BRAIN UH3 NS103550 and Hope for Depression Research Foundation. DW research was supported by Michael J. Fox Foundation, Burroughs-Wellcome Career Award for Medical Scientists, and UCSF Weill Institute for Neurosciences. JaC research was funded by R01MH119382. SMi research was supported by NIH K23NS097576. RS research was funded by NIH R01NS100874, R01NS119301, R01NS127435, and P50HD103555. CO research was funded by the Thiemann Foundation and by NIH UH3NS100544. AG research was supported by NIH R01NS096008 and NSF Career Award 1553482. WG acknowledges grant funding from NIH UH3NS100549. HT research was supported by the Medical Research Council UK (MC_UU_00003/2, MR/V00655X/1, and MR/P012272/1), the NIHR, Oxford Biomedical Research Centre, and the Rosetrees Trust. JV gratefully acknowledges grant support by the Deutsche Forschungsgemeinschaft within the framework of CRC-TRR 295 (Retune). PaS, TC, and PeS research was funded by the University of Queensland through the Queensland Brain Institute in partnership with Medtronic. JeC work was supported by the Canadian Institutes of Health Research within the funding framework Network of European Funding for Neuroscience Research (NEURON) under the ERA-NET scheme of the European Commission. ML research was supported by NIH 5K23NS099441. CR research was supported by NIH UH3NS103550. JH research was supported by NIH R01DC014034, U01DC017844, UH2NS095548, and U01NS098968. MO served as a consultant for the Parkinson’s Foundation and has received research grants from NIH, Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation, DBS research was supported by: NIH R01 NR014852 and R01NS096008, and PI of the NIH R25NS108939 Training Grant. Publisher Copyright: Copyright © 2023 Wong, Mayberg, Wang, Richardson, Halpern, Krinke, Arlotti, Rossi, Priori, Marceglia, Gilron, Cavanagh, Judy, Miocinovic, Devergnas, Sillitoe, Cernera, Oehrn, Gunduz, Goodman, Petersen, Bronte-Stewart, Raike, Malekmohammadi, Greene, Heiden, Tan, Volkmann, Voon, Li, Sah, Coyne, Silburn, Kubu, Wexler, Chandler, Provenza, Heilbronner, Luciano, Rozell, Fox, de Hemptinne, Henderson, Sheth and Okun.

PY - 2023/1/27

Y1 - 2023/1/27

N2 - The deep brain stimulation (DBS) Think Tank X was held on August 17–19, 2022 in Orlando FL. The session organizers and moderators were all women with the theme women in neuromodulation. Dr. Helen Mayberg from Mt. Sinai, NY was the keynote speaker. She discussed milestones and her experiences in developing depression DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging DBS technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank X speakers was that DBS has continued to expand in scope however several indications have reached the “trough of disillusionment.” DBS for depression was considered as “re-emerging” and approaching a slope of enlightenment. DBS for depression will soon re-enter clinical trials. The group estimated that globally more than 244,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year’s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia, and Australia; cutting-edge technologies, closed loop DBS, DBS tele-health, neuroethics, lesion therapy, interventional psychiatry, and adaptive DBS.

AB - The deep brain stimulation (DBS) Think Tank X was held on August 17–19, 2022 in Orlando FL. The session organizers and moderators were all women with the theme women in neuromodulation. Dr. Helen Mayberg from Mt. Sinai, NY was the keynote speaker. She discussed milestones and her experiences in developing depression DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging DBS technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank X speakers was that DBS has continued to expand in scope however several indications have reached the “trough of disillusionment.” DBS for depression was considered as “re-emerging” and approaching a slope of enlightenment. DBS for depression will soon re-enter clinical trials. The group estimated that globally more than 244,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year’s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia, and Australia; cutting-edge technologies, closed loop DBS, DBS tele-health, neuroethics, lesion therapy, interventional psychiatry, and adaptive DBS.

KW - Parkinson’s disease

KW - adaptive DBS

KW - artificial intelligence

KW - deep brain stimulation (DBS)

KW - dystonia

KW - epilepsy

KW - interventional psychiatry

KW - neuroethics

UR - http://www.scopus.com/inward/record.url?scp=85148370337&partnerID=8YFLogxK

U2 - 10.3389/fnhum.2022.1084782

DO - 10.3389/fnhum.2022.1084782

M3 - Article

AN - SCOPUS:85148370337

SN - 1662-5161

VL - 16

JO - Frontiers in Human Neuroscience

JF - Frontiers in Human Neuroscience

M1 - 1084782

ER -

Wong JK, Mayberg HS, Wang DD, Richardson RM, Halpern CH, Krinke L et al. Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation. Frontiers in Human Neuroscience. 2023 Jan 27;16:1084782. doi: 10.3389/fnhum.2022.1084782